Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Hematologic Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNo Longer AvailableNCT05503550
What this trial is testing

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Early research (Phase 1)Looking for participantsNCT06227026
What this trial is testing

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaDiffuse Large B Cell Lymphoma
University of Utah 10
Testing effectiveness (Phase 2)Study completedNCT00559091
What this trial is testing

Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia

Who this might be right for
Acute Myelocytic Leukemia
Jewish General Hospital 18
Testing effectiveness (Phase 2)UnknownNCT03902197
What this trial is testing

CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients

Who this might be right for
Acute Lymphoblastic Leukemia
Xuanwu Hospital, Beijing 50
Early research (Phase 1)Study completedNCT01222780
What this trial is testing

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Who this might be right for
SarcomaNeuroblastomaWilms Tumor+3 more
Acrotech Biopharma Inc. 22
Testing effectiveness (Phase 2)UnknownNCT01240525
What this trial is testing

Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
University College, London 114
Not applicableEnded earlyNCT00608517
What this trial is testing

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Vanderbilt-Ingram Cancer Center 6
Early research (Phase 1)UnknownNCT05007418
What this trial is testing

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sorrento Therapeutics, Inc. 54
Testing effectiveness (Phase 2)Ended earlyNCT05272813
What this trial is testing

Investigate the Efficacy and Safety of MS-553 in CLL/SLL

Who this might be right for
Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. 13
Testing effectiveness (Phase 2)Study completedNCT03839446
What this trial is testing

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Who this might be right for
Acute Myeloid Leukemia
Robert Redner, MD 16
Testing effectiveness (Phase 2)UnknownNCT01002703
What this trial is testing

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Leipzig 50
Testing effectiveness (Phase 2)Study completedNCT03067155
What this trial is testing

CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.

Who this might be right for
Hematological MalignanciesCMV Infection
University Hospital, Ghent 1
Early research (Phase 1)Ended earlyNCT04123418
What this trial is testing

WVT078 in Patients With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma (MM)
Novartis Pharmaceuticals 56
Early research (Phase 1)Active Not RecruitingNCT04874480
What this trial is testing

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Who this might be right for
Recurrent LeukemiaRefractory Leukemia
M.D. Anderson Cancer Center 9
Early research (Phase 1)Looking for participantsNCT06799026
What this trial is testing

Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
David Avigan 25
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT00044018
What this trial is testing

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 102
Early research (Phase 1)UnknownNCT04295018
What this trial is testing

BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Study completedNCT02509546
What this trial is testing

8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center 20
Early research (Phase 1)Looking for participantsNCT05963217
What this trial is testing

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Who this might be right for
Relapsed or Refractory CD19+ B-cell LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
University Health Network, Toronto 19
Next Page